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Background: The high cost and low level of cancer survival urge the finding of new drugs having better
mechanisms. There is a high trend of patients to be “back to nature” and use natural products as an alternative way
to cure cancer. The fact is that some of available anticancer drugs are originated from plants, such as taxane,
vincristine, vinblastine, pacitaxel. Curcumin (diferuloylmethane), a dietary pigment present in Curcuma longa
rizhome is reported to induce cell cycle arrest in some cell lines. Other study reported that genistein isolated from
Glycine max seed inhibited phosphorylation of cdk1, gene involved during G2/M transition and thus could function
as G2 checkpoint abrogator. The inhibition of cdk1 phosphorylation is one of alternative strategy which could
selectively kill cancer cells and potentially be combined with DNA damaging agent such as curcumin.
Methods: T47D cell line was treated with different concentrations of curcumin and genistein, alone or in
combination; added together or with interval time. Flow Cytometry and MTT assay were used to evaluate cell cycle
distribution and viability, respectively. The presence of apoptotic cells was determined using acridine
orange-ethidium bromide staining.
Results: In this study curcumin induced G2 arrest on p53 deficient T47D cells at the concentration of 10 μM.
Increasing concentration up to 30 μM increased the number of cell death. Whilst genistein alone at low
concentration (≤10 μM) induced cell proliferation, addition of genistein (20 μM) 16 h after curcumin resulted in
more cell death (89%), 34% higher than that administered at the same time (56%). The combination treatment
resulted in apoptotic cell death. Combining curcumin with high dose of genistein (50 μM) induced necrotic cells.
Conclusions: Genistein increased the death of curcumin treated T47D cells. Appropriate timing of administration
and concentration of genistein determine the outcome of treatment and this method could potentially be
developed as an alternative strategy for treatment of p53 defective cancer cells.
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Most of chemotherapeutic drugs such as etoposide, cis-
plastin, doxorubicin and camptotechin induce DNA dam-
age on cancer cells. These DNA (deoxy nucleid acid)
damaging agents arrest or delay cell cycle progression,
allowing time for DNA repair. This mechanism of repair
functions to ensure that division only occur on cells carry-
ing complete DNA, not mutated or damage. If the damage
is beyond repair, the cells may permanently enter cellular
senescence or undergo apoptosis [1,2]. The mechanism of* Correspondence: p.astuti@gmail.com
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reproduction in any medium, provided the orcell cycle arrest is mediated by ATM (ataxia
telangiectasia-mutated protein kinase) or ATR (ATM and
Rad3-related protein kinase) through the activation of
Ser/Thr kinases checkpoint kinase 1 (Chk1) and check-
point kinase 2 (Chk2). The activation of Chk1 and Chk2
in turn modulates phosphorylation events such as phos-
phorylation of cdc25 phosphatases which normally acti-
vate cdk1 in G2/M boundary and result in cell cycle arrest
at the G2/M or S phase [3]. Based on oncologic point of
view, this mechanism of repair is beneficial to normal cells
in that they have mechanism to reduce toxic effect of the
chemotherapeutic agents. However, this system of protec-
tion limits the efficacy of chemotherapy on cancer cells.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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on G1 phase depends on tumor suppressor protein p53.
Normal cells carrying wild type p53 are able to arrest at
G1, S and G2 phase, whilst cells having defect on p53
gene, which occur on >50% of tumor, would progress
through S phase and arrest at G2 phase [4-6]. Any
agents which capable of abrogating cell cycle arrest at
G2 phase would induce premature entry into mitosis,
with cells still carry damaged DNA and resulting in
apoptosis. Inducing mitotic catastrophe in G2 arrested
cell can be used as a strategy to selectively kill tumor cell
lacking functional p53, and at the same time provide op-
portunities for normal cells to survive.
Although conventional chemotherapy using DNA
damaging agents resulting in tumor cell death, the dele-
terious side effects are well known. Furthermore, the
high cost of treatment urges the finding of selective
agents with more affordable price. Currently, there is
trend of patients to use natural medicine as an alterna-
tive therapy against cancer. The fact that some of avail-
able anticancer drugs such as taxan, vincristine,
vinblastine and pacitaxel are medicinal plant origin, pro-
vide great opportunities to effectively use natural com-
pounds to treat cancer. A lot of studies have been
conducted to examine the potential of natural com-
pounds against cancer with one of example is curcumin.
Curcumin (diferuloylmethane) is dietary pigment and
presence as major compound in Curcuma longa
rizhome. This compound has a potential to be developed
as anticancer agent and was in phase II clinical trials
[7,8]. Curcumin was reported to be cytotoxic and in-
active in normal and primary cells. In mouse embryonic
fibroblast line C3H/10 T1/2, rat embryonic fibroblasts,
and human foreskin fibroblast, curcumin did not induce
cell death, whereas in cancer cells it stimulated cell
death through mechanism of apoptosis [8-12]. Curcumin
also induced cell cycle arrest in colorectal tumor line
HCT116, medulloblastoma and human acute promyelo-
cytic leukemia HL-60 [12-14]. The ability to induce cell
death increased with addition of piperine, the major
compound of Piper nigrum L) which reportedly increase
the bioavailability of curcumin [14-17].
The activity of curcumin as anticancer agent can be
increased by combination with compounds having effect
as G2 checkpoint abrogator. Flavonoid is natural poly-
phenolic compounds potential to be developed as antic-
ancer agents [18,19]. Isoflavonoid genistein was found to
be active in pancreatic cells by modulating cell cycle and
inhibition of angiogenesis [20,21]. Following administra-
tion of irinotecan, this compound inhibited phosphoryl-
ation of cdk1 mediated by wee1 kinase, a negative
regulator of cdk1 kinase activity [22]. Inhibition of cdk1
phosphorylation could be a potential strategy to abrogate
G2 checkpoint activation [23].Methods
Materials
Genistein was obtained from Sigma, curcumin was
kindly given by Dr. Hilda Ismail, 86% purity by HPLC
(High Pressure Liquid Chromatography). They were dis-
solved in ethanol absolute, divided into aliquots, and
stored frozen at −20°C.
Cell lines and culture conditions
T47D (Human ductal breast epithelial tumor cell line)
was cultured in RPMI 1640 media supplemented with
10% Fetal Bovine Serum (Gibco) 2% Penicillin - Strepto-
mycin (Gibco), dan 0.5% Fungizon (Gibco), 2% Sodium
bicarbonate (Gibco) and HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) (Invitrogen). Cell lines
were maintained at 37°C in a humidified incubator con-
taining 5% CO2.
Cell cycle analysis
Treated cells were harvested using trypsine and washed
three times with 1×PBS. Cell pellets were resuspended
with 500 μl staining solution (40 μg/ml propidium iodide
(Sigma) and 500μg/ml RNase A (Sigma), covered with
aluminium foil and incubated at 37°C for 30 minutes.
Cells were analysed using FACS (Fluorescence Activated
Cell Sorting) Calibur (BD).
Viability assay
A hundred μl of media containing 5x103 cells was added to
96-well plate and incubated for 48 hours until 70% – 80%
confluent. Curcumin was added alone or in combination
with genistein, added together or in interval time. Cells
were incubated at 37°C in CO2 incubator. Following the
treatment, cells were gently washed with 1X PBS (Phos-
phate Buffer Saline), and 100 μl of MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
0.5 mg/ml was added to the well. The cells were incubated
for 4 hours at 37°C and the reaction was stopped by adding
100 μl SDS (sodium dodecyl sulfate) 10%. The plates were
incubated overnight and read in microplate reader (Bio-
Rad) at 595 nm.
Apoptotic assay
T47D cells were plated onto 6 well plate containing
coverslip and treated with curcumin, genistein or in
combination as indicated. Following the treatment, the
cells on coverslip were treated with ethidium bromide-
acridine orange and the cells were analysed under fluor-
escence microscope (Carl Zeiss).
Results
Curcumin induced G2 arrest in T47D cells
To study the mechanism of action of curcumin in vitro,
we have tested the effect of increasing concentration of
Table 1 Cell cycle distribution of T47D cells after
treatment of different concentration of curcumin
overnight
Treatment Sub G1 (%) G1 (%) S (%) G2 (%)
Control 2.32 37.23 27.88 25.34
10 μM curcumin 1.26 22.74 19.30 44.13
20 μM curcumin 12.78 22.13 13.79 37.43
30 μM curcumin 14.28 28.38 11.39 39.57
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were treated at different concentration of curcumin and
incubated overnight. As shown in Table 1 and Figure 1,
curcumin at 10 μM induced G2 arrest in T47D cells.
The cells showed a strong block in the G2/M phase of
the cell cycle (reaching 44% compared with 25% in the
untreated controls). Increasing the concentration up to
30 μM did not significantly increase G2/M population.
Instead, it appeared a marked sub-G1 peak (from 2% in
control cells to 12% at 20 μM and 14% at 30 μM of trea-
ted cells), because of the presence of dead cells. Adding
curcumin at low as 5 μM did not induce cell cycle arrest
(data not shown). These data demonstrate that curcumin
at 10 μM arrest T47D cells at G2/M with little
cytotoxicity.
Genistein abrogated G2 arrest induced by curcumin
In an attempt to discover natural compounds that dis-
rupt G2 checkpoint in cancer cells, we used genistein,
an inhibitor of cdk1 phosphorylation [22]. We examine
the ability of different concentration of genistein in
modulating G2 arrest induced by curcumin. Firstly, weFigure 1 Cell cycle analysis of T47D cell using flowcytometry after tre
plated onto 6 well plate and treated overnight with (A) control untreated c
curcumin. Arrow indicated the presence of sub G1 population.activated the G2 checkpoint by adding curcumin at the
concentration of 10 μM overnight. Sixteen hours after
DNA damage, the cells were treated with different con-
centration of genistein for another 24 hours. The cells
were harvested and the cell cycle distribution was ana-
lysed. Indeed, as shown in Table 2 and Figure 2, genis-
tein at concentration of 20 μM abrogated the G2/M
block induced by curcumin, decreasing G2/M popula-
tion from 28% in curcumin only treated cells to 6% in
combination with 20 μM genistein. Increasing concen-
tration of genistein up to 50 μM did not significantly re-
duce the shift of G2/M population. The G2/M
population only decreased to 10% in combination with
50 μM genistein. Combination of curcumin with genis-
tein increased the subG1 population which represents
dead cells, from 2% to 44% (20 μM genistein) and 47%
(50 μM genistein).
Addition of genistein following G2 arrest induced by
curcumin resulted in more cell death
To check the effect of combination of genistein with
curcumin on cell viability, we treated the cells with cur-
cumin, genistein and in combination with various inter-
val times by means of MTT assay. The experiments were
performed in three replicates. Previously we found that
curcumin at concentration of 10 μM induced G2/M ar-
rest with little toxicity. In this experiment we confirmed
the finding that treatment curcumin at given concentra-
tion retained the viability of cells of 83.66%. An attempt
to increase the sensitivity of this compound in inducing
cell death is conducted by addition of genistein. Table 3
shows that genistein alone at low concentration of 5 andatment with different concentration of curcumin. T47D cells were
ells, (B) 10 μM curcumin, (C), 20 μM curcumin and (D) 30 μM
Table 2 Cell cycle distribution of T47D cells after treatment of 10 μM curcumin overnight followed by 20 μM genistein
or 50 μM genistein
Treatment Sub G1 (%) G1 (%) S (%) G2 (%)
Control 8.51 48.85 11.13 18.52
10 μM curcumin 2.71 31.12 18.86 28.22
10 μM curcumin + 20 μM genistein 44.25 39.66 5.72 6.44
10 μM curcumin + 50 μM genistein 47.47 29.17 6.76 10.14
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reaching 191.80% and 171.22% respectively. Increasing
concentration to 20 μM maintained the viability of
90.41%, whereas high concentration of 50 μM induced
61.28% cell death. In this study we found that genistein
(20 μM) which was added 16 hours after 10 μM curcu-
min resulted in more cell death, from 83.66% viability in
curcumin only treated cells to only 10.88% in combin-
ation. Adding higher concentration of genistein (50 μM)
only slightly increased the percentage of cell death
(8.48%). Interestingly, in this study we found that adding
genistein following DNA damage induced by curcumin
produced more cell death (89.12%) compared to adding
at the same time (56.51%). The effect of inducing cell
death by combination of curcumin and genistein were
confirmed by observing the morphology of the cells after
treatment with curcumin or in combination with genis-
tein using ethidium bromide and acridine – orange
double staining under fluoresence microscope. The pres-
ence of apoptotic cells were shown as orange to red
population as compared to healthy green cell population
[24]. As shown in Figure 3, only few dead cells were
observed in curcumin only treated cells. However, com-
bining curcumin with genistein resulted in highFigure 2 Cell cycle analysis of T47D cell using flowcytometry after tre
6 well plate and treated with (A) control untreated cells, (B) 10 μM curcum
(D) 10 μM curcumin overnight followed by 50 μM genistein. Arrow indicataccumulation of apoptotic cells. Combination with high
concentration of genistein induced the presence of nec-
rotic cells, as appear as a form of debris (Figure 3).
Discussion
Conventional chemotherapeutics have been widely ap-
plied in treatment against various type of cancer. The ef-
fectiveness of these therapies depends on their ability to
kill proliferating cancer cells by damaging their DNA
and inducing apoptosis. The cell responds to DNA dam-
age to induce cell cycle arrest at any stage, ensuring the
damage is repaired prior to enter subsequent phase of
cell cycle [25]. This mechanism of control is function to
maintain genetic integrity, with the failure of repair
resulted in mutations and eventually cell death. How-
ever, these agents convey some drawbacks in which they
developed resistance to DNA damage-induced cell kill-
ing and they are also toxic to actively proliferating nor-
mal cells.
One of the characteristics of tumor growth is uncon-
trolled cell proliferation as a result of loss in normal cell
cycle control. Currently there is an increasing of interest
to target cell cycle in effort to find targeted anticancer
therapies [26-29]. In fact >50% of human cancer haveatment with curcumin and genistein. T47D cells were plated onto
in, (C), 10 μM curcumin overnight followed by 20 μM genistein and
ed the presence of subG1 population.
Table 3 Persentage of cell viability following the
administration of curcumin, genistein and combination
(n =3)
No Treatment % viability ± SE
1 Curcumin 10 μM 83.66 ± 8.24
2 Genistein 5 μM 191.80 ± 8.94
3 Genistein 10 μM 171.22 ± 6.63
4 Genistein 20 μM 90.41 ± 2.13
5 Genistein 50 μM 38.72 ±3.99
6 Curcumin 10 μM + Genistein 20 μM* 10.88 ± 1.85
7 Curcumin 10 μM + Genistein 50 μM* 2.40 ± 0.59
8 Curcumin 10 μM + Genistein 20 μM** 43.49 ± 4.90
9 Curcumin 10 μM + Genistein 50 μM** 15.83 ± 0.88
** Curcumin and genistein were added at the same time. * Genistein was
added 16 hours after the addition of curcumin. These data represent minimal
two independent experiments.
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essential component for apoptosis induction in response
to DNA damage and also a component of cell cycle
checkpoint. The loss of p53 resulted in cell reliance on
G2 phase checkpoint in response to DNA damage indu-
cing agent which easily can be bypassed by adding G2
phase checkpoint inhibitors to induce aberrant mitosis
and eventually increased cell death [30,31].
In Indonesia, there is a high trend of using herbal medi-
cine in promoting health with some of the herbal materials
commonly used are curcuma rizhome (Curcuma longa L)
and soy bean (Glycin max) which contain bioactive com-
pound of curcumin and genistein, respectively. The bioac-
tivities of these natural products have been widely
reported [13,15,21,32]. In this study we tested the com-
bined effects of genistein with curcumin in inhibiting the
growth of cancer cells. As was seen in T47D cells, curcu-
min induces G2 phase arrest, similar as reported by others
[12,13] and genistein abrogated the G2 checkpoint con-
trols induced by curcumin. The combination of the two
agents reduced cell viability up to seven fold, in compari-
son of adding the agent alone. Since many of cancers haveFigure 3 Morphology of cells treated with curcumin, genistein or in c
with (A) control cells, (B) 10 μM curcumine only, (C) curcumin (10 μM) was
(D) curcumin (10 μM) was added overnight followed by treatment with gedefective of checkpoint control due to the loss of p53 gene,
further deregulation of this mechanism of control can re-
sult in increased apoptotic cell death.
In this study we demonstrated the success of applying
strategies to deliver a more cancer-specific cytotoxic
treatment by synthetic lethality targeting p53 defective
cancer cells. These synthetic lethality strategies are cur-
rently being used to search new drugs or targets within
specific tumor types such as inhibition of Chk1 in p53
mutant cancers to achieve better outcomes [33,34]. Using
this strategy, reduced side effects and better outcomes
could be achieved since doses of chemotherapeutic agents
can be reduced at least twofold [35-37]. In this study we
showed the selectivity of synthetic lethality strategy by
targeting the loss of function of p53 and application of
DNA damage inducing agent. In T47D, p53 deficient
cells, survival of the cells following DNA damage are
dependent on activation of the Chk1 pathway to induce
G2 cell cycle arrest and DNA repair. Disruption of this
Chk1-dependent pathway by genistein can selectively
sensitize cells to exit G2 phase before the damage are
repaired and eventually the cells undergo apoptosis. In
this study we demonstrated that adding combination of
curcumin followed by genistein on T47D cells showed
greater cell death, indicating the importance of appropri-
ate timing of administration in inducing cell death.
Similar study was reported by Tse et al. [38], when com-
bining topoisomerase I posion and checkpoint inhibitor
7-hydroxystaurosporine in human colon cancer. Sequen-
tial treatment of SN-38 followed by UC-01, a Chk1 inhibi-
tor, resulted in enhanced apoptosis in p53 mutant cells,
and this was proven to be effective in p53 mutant but to
lesser degree in p53 intact cells.
Collectively, these studies provide a new insight in
using naturally derived agents to treat cancer with se-
lective methods to achieve better outcomes. This ap-
proach is based on understanding that in the synthetic
lethal strategy targeting p53 defective cells, the loss of
stress response mechanism can reduce cell viability. Thisombination. T47D cells were plated onto 6 well plate and treated
added overnight followed by treatment with genistein (20 μM),
nistein (50 μM).
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of compensatory systems can generate complete loss of
cell viability [33,39].
Conclusions
In this study we demonstrated that genistein increased
the death of curcumin treated T47D cells. We showed
that the inhibition of checkpoint pathway is generated
by genistein and the selectivity is achieved by the loss of
p53 function in T47D cells and application of curcumin.
Since the main active compounds used in this study are
natural product origin, it is expected that this study
could support the rational of using traditional medicines
for maintaining health. Appropriate use of these natural
products could help cancer patients in using alternative
therapies with scientific evidence based medicines.
Competing interest
The authors declare that there is no conflict of interest related to this
publication.
Authors’ contributions
PA contributes to the concept, design, data acquisition, analysis and
interpretation; preparation of the manuscript and approval of final article.
EDU contributes to data acquisition and analysis, preparation of the
manuscript and approval of final article. Part of the data was collected for
her master thesis. AWN participated in data acquisition and analysis and
helped to draft the manuscript. SS participated in the design and
coordination, preparation of the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
This work was performed with Hibah Berkualitas Prima Faculty of Pharmacy
UGM 2011. We are grateful to Dr. Hilda Ismail for the donation of curcumin
used in these experiments.
Author details
1Pharmaceutical Biology Department, Faculty of Pharmacy, Universitas
Gadjah Mada, Yogyakarta, Indonesia. 2Pharmacy Department, Faculty of
Medicinal and Health Sciences, Universitas Jenderal Soedirman, Purwokerto,
Indonesia. 3Sekolah Tinggi Ilmu Farmasi (STIFAR), Pharmacy Foundation,
Semarang, Indonesia. 4Pharmaceutical Chemistry Department, Faculty of
Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Received: 11 September 2012 Accepted: 27 November 2012
Published: 30 November 2012
References
1. Kastan BM, Bartek J: Cell-cycle checkpoints and cancer. Nature 2004,
432:316–323.
2. Eastman A: Cell cycle checkpoints and their impact on anticancer
therapeutic strategies. J Cell Biochem 2004, 91:223–231.
3. Lukas J, Lukas C, Bartek J: Mammalian cell cycle checkpoints: signaling
pathways and their organization in space and time. DNA Repair (Amst)
2004, 3:997–1007.
4. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997,
88:323–331.
5. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, Sun Y:
Radiosensitization of p53 Mutant Cells by PD0166285, a Novel G2
Checkpoint Abrogator. Cancer Res 2001, 61:8211–8217.
6. Eastman A, Kohn EA, Brown MK, Rathman J, Livingstone M, Blank DH,
Gribble DW: A Novel Indolocarbazole, ICP-1, Abrogates DNA Damage
induced Cell Cycle Arrest and Enhances Cytotoxicity: Similarities and
Differences to the Cell Cycle Checkpoint Abrogator UCN-011. Mol Cancer
Ther 2002, 1:1067–1078.7. Sharma RA, Gescher AJ, Steward WP: Curcumin: the story so far. Eur J
Cancer 2005, 41:1955–1968.
8. Chauhan DP: Chemotherapeutic potential of curcumin for colorectal
cancer. Curr Pharm 2002, 8:1695–1706.
9. Jiang MC, Yang-Yen HF, Yen JJ, Lin JK: Curcumin induces apoptosis in
immortalized NIH 3 T3 and malignant cancer cell lines. Nutr Cancer 1996,
26:111–120.
10. Karunagaran D, Rashmi R, Kumar TR: Induction of apoptosis by curcumin
and its implications for cancer therapy. Curr Cancer Drug Targets 2005,
5:117–129.
11. Song G, Mao YB, Cai QF, Yao LM, Ouyang GL, Bao SD: Curcumin induces
human HT-29 colon adenocarcinoma cell apoptosis by activating p53
and regulating apoptosis-related protein expression. Braz J Med Biol Res
2005, 38:1791–1798.
12. Tan TW, Tsai HR, Lu HF, Lin HL, Tsou MF, Lin YT, Tsai HY, Chen YF,
Chung JG: Curcumin-induced cell cycle arrest and apoptosis in human
acute promyelocytic leukemia HL-60 cells via MMP changes and
caspase-3 activation. Anticancer Res 2006, 26(6B):4361–4371.
13. Jiang Z, Jin S, Yalowich JC, Brown KD, Rajasekaran B: The Mismatch Repair
System Modulates Curcumin Sensitivity through Induction of DNA
Strand Breaks and Activation of G2-M Checkpoint. Mol Cancer Ther 2010,
9(3):558–568.
14. Elamin MH, Shinwari Z, Hendrayani SF, Al-Hindi H, Al-Shail E, Khafaga Y,
Al-Kofide A, Aboussekhra A: Curcumin inhibits the Sonic Hedgehog
signaling pathway and triggers apoptosis in medulloblastoma cells.
Mol Carcinog 2010, 49(3):302–314.
15. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB: Bioavailability of
Curcumin: Problems and Promises. Mol Pharm 2007, 4(6):807–818.
16. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB,
Sung B, Tharakan ST, Misra K, Priyadarsini IK, Rajasekharan KN, Aggarwal BB:
Biological activities of curcumin and its analogues (Congeners) made by
man and Mother Nature. Biochem Pharmacol 2008, 76(11):1590–1611.
17. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, Liu S,
Dontu G, Wicha MS: Targeting breast stem cells with the cancer
preventive compounds curcumin and piperine. Breast Cancer Res Treat
2010, 122(3):777–785.
18. Li W, Fan J, Bertino JR: Selective sensitization of retinoblastoma
protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated
inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res 2001,
61(6):2579–2582.
19. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH: Inactivation of nuclear
factor kappaB by soy isoflavone genistein contributes to increased
apoptosis induced by chemotherapeutic agents in human cancer cells.
Cancer Res 2005, 65(15):6934–6942.
20. Buchler P, Reber HA, Buchler MW, Friess H, Lavey RS, Hines OJ:
Antiangiogenic activity of genistein in pancreatic carcinoma cells is
mediated by the inhibition of hypoxia-inducible factor-1 and the
down-regulation of VEGF gene expression. Cancer 2004, 100(1):201–210.
21. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA,
Abbruzzese J, Sarkar FH: Molecular evidence for increased antitumor
activity of gemcitabine by genistein in vitro and in vivo using
an orthotopic model of pancreatic cancer. Cancer Res 2005,
65(19):9064–9072.
22. Papazisis KT, Kalemi TG, Zambouli D, Geromichalos GD, Lambropoulos AF,
Kotsis A, Boutis LL, Kortsaris AH: Synergistic effects of protein tyrosine
kinase inhibitor genistein with camptothecins against three cell lines
in vitro. Cancer Lett 2006, 233(2):255–264.
23. Leijen S, Beijnen JH, Schellens JH: Abrogation of the G2 checkpoint by
inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor
cells to DNA-damaging agents. Curr Clin Pharmacol 2010, 5(3):186–191.
24. Baskić D, Popović S, Ristić P, Arsenijević NN: Analysis of cycloheximide-
induced apoptosis in human leukocytes: fluorescence microscopy using
annexin V/propidium iodide versus acridin orange/ethidium bromide.
Cell Biol Int 2006, 30(11):924–932.
25. Medema RH, Macůrek L: Checkpoint control and cancer. Oncogene 2012,
31(21):2601–2613.
26. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.
Cell 2011, 144:646–674.
27. Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, Kuszpit K,
Zasadny K, Hallin M, Hallin J, Wong A, Buckman D, Sun G, Qiu M, Anderes K,
Christensen JG: PF-00477736 mediates checkpoint kinase 1 signaling
Astuti et al. DARU Journal of Pharmaceutical Sciences 2012, 20:82 Page 7 of 7
http://www.darujps.com/content/20/1/82pathway and potentiates docetaxel-induced efficacy in xenografts.
Clin Cancer Res 2009, 15:4630–4640.
28. Hagimori K, Fukuda T, Hasegawa Y, Omura S, Tomoda H: Fungal
malformins inhibit bleomycin-induced G2 checkpoint in Jurkat cells.
Biol Pharm Bull 2007, 30(8):1379–1383.
29. Warrener R, Beamish H, Burgess A, Waterhouse NJ, Giles N, Fairlie D,
Gabrielli B: Tumor cell-selective cytotoxicity by targeting cell cycle
checkpoints. FASEB J 2003, 17:1550–1552.
30. Mukhopadhyay UK, Senderowicz AM, Ferbeyre G: RNA silencing of
checkpoint regulators sensitizes p53-defective prostate cancer cells to
chemotherapy while sparing normal cells. Cancer Res 2005, 65:2872–2881.
31. Ma CX, Janetka JW, Piwnica- Worms H: Death by releasing the breaks:
CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011, 17:88–96.
32. Wu AH, Ziegler RG, Nomura AM, West DW, Kolonel LN, Horn-Ross PL,
Hoover RN, Pike MC: Soy intake and risk of breast cancer in Asians and
Asian Americans. Am J Clin Nutr 1998, 68(Suppl 6):1437S–1443S.
33. Gabrielli B, Brooks K, Pavey S: Defective cell cycle checkpoints as targets
for anti-cancer therapies. Front Pharmacol 2012, 3(9):1–6.
34. Kuiken HJ, Beijersbergen RL: Exploration of synthetic lethal interactions as
cancer drug targets. Future Oncol 2010, 6:1789–1802.
35. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S,
Ninkovic S, Chen P, Nichols T, O’Connor P, Anderes K: Breaching the DNA
damage checkpoint via PF-00477736, a novel small-molecule inhibitor of
checkpoint kinase1. Mol Cancer Ther 2008, 7:2394–2404.
36. Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M, Ma S,
Moler EJ, Ni ZJ, Lopes De Menezes DE, Hibner B, Gesner TG, Schwartz GK:
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity
of topoisomerase I poisons invitro and invivo. Clin Cancer Res 2007,
13:591–602.
37. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL,
Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S,
Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM:
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint
abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther
2008, 7:2955–2966.
38. Tse A, Schwartz G: Potentiation of cytotoxicity of topoisomerase I poison
in human colon carcinoma cells by concurrent and sequential treatment
with the checkpoint inhibitor 7-hydroxystaurosporine involves disparate
mechanisms resulting in different pharmacological endpoints. Cancer Res
2004, 64:6635–6644.
39. Kaelin WG Jr: The concept of synthetic lethality in the context of
anticancer therapy. Nat Rev Cancer 2005, 5:689–698.
doi:10.1186/2008-2231-20-82
Cite this article as: Astuti et al.: Genistein abrogates G2 arrest induced
by curcumin in p53 deficient T47D cells. DARU Journal of Pharmaceutical
Sciences 2012 20:82.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
